Rate My Professor Mark Walker

Professor Mark Walker is a Professorial Research Fellow and Group Leader at the Institute for Molecular Bioscience, University of Queensland. He holds a Doctor of Philosophy from the University of Queensland. His research centers on the pathogenesis of Group A Streptococcus (Streptococcus pyogenes; GAS or Strep A), elucidating mechanisms by which this pathogen causes a spectrum of diseases from mild suppurative infections such as pharyngitis, impetigo, scarlet fever, and cellulitis to severe invasive conditions including septicemia, streptococcal toxic shock syndrome, and necrotizing fasciitis. Key areas include host-pathogen interactions, bacterial virulence factors, inflammasome activation, IL-1β signaling, plasminogen activation, metal homeostasis, prophage exotoxins, cholesterol-dependent cytolysins, immune evasion strategies, and antimicrobial resistance in superbugs.

Walker leads the Walker Group in advancing Strep A vaccine development, including multivalent T-antigen-based vaccines, self-adjuvanting constructs, and mRNA vaccines through collaborations such as with Moderna. He has authored over 300 publications, including landmark works like 'Pathogenesis, epidemiology and control of Group A Streptococcus infection' (Nature Reviews Microbiology, 2023), 'An mRNA vaccine encoding five conserved Group A Streptococcus antigens' (Nature Communications, 2025), 'Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes' (Nature Communications, 2020), and 'Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis' (Science Translational Medicine, 2020). As an NHMRC L3 Investigator Fellow, he has secured extensive funding, including NHMRC Investigator Grants (2026-2030), CARB-X grants, and NHMRC Development Grants for vaccine refinement. Walker supervises PhD students, contributes to media expertise on streptococcal infections, and addresses global health burdens, particularly in Indigenous Australian communities, through innovative antibiotic adjuvants and ionophore therapies like PBT2.